Camac Fund, LP 4
4 · Pasithea Therapeutics Corp. · Filed Sep 6, 2022
Insider Transaction Report
Form 4
Shahinian Eric
Other
Transactions
- Purchase
Common Stock
2022-09-02$1.14/sh+11,507$13,105→ 1,702,310 total(indirect: See footnote) - Purchase
Common Stock
2022-09-01$1.13/sh+55,646$62,630→ 1,690,803 total(indirect: See footnote) - Purchase
Common Stock
2022-09-06$1.13/sh+21,748$24,632→ 1,724,058 total(indirect: See footnote)
Footnotes (1)
- [F1]The shares are held by Camac Fund, LP. ("Camac Fund"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC.